Search Results for “EU” – Page 374 – media

OTC Viagra– Pfizer snags nod for nonprescription sales of the little blue pill for men in the U.K.

Pfizer has won a first approval for OTC Viagra. Viagra Connect, the Pfizer OTC name for its blockbuster erectile dysfunction drug, has been approved for sale in the U.K.
- Source: Fiercepharma
- 558
- December 13, 2017
erectile dysfunction drug New Approvals OTC Viagra Pfizer
Dengue vaccine not deadly–Sanofi, Philippines

A world-first dengue vaccination programme in the Philippines that was suspended over safety concerns will not cause anyone who was immunised to die, drug manufacturer Sanofi and local authorities said on Monday
- Source: msn
- 687
- December 13, 2017
Company Insight dengue vaccination programme Sanofi
Medical sensors market worth $15.01 billion by 2022

The global medical sensors market is estimated to reach $15.01 billion by 2022, at a CAGR of 8.5% between 2016 and 2022. People are increasingly adopting home healthcare services owing to the rising costs of medical treatments in hospitals and medical care clinics. With this, the demand for various healthcare devices is expected to increase in the next few years.
- Source: todaysmedicaldevelopments
- 421
- December 12, 2017
Market Views medical sensors
Gene therapy shows promise against blood-clotting disease

Gene therapy has freed 10 men from nearly all symptoms of hemophilia for a year so far, in a study that fuels hopes that a one-time treatment can give long-lasting help and perhaps even cure the blood disease.
- Source: Usnews
- 518
- December 12, 2017
blood disease gene hemophilia
Alexion and Halozyme Enter License Agreement for ENHANZE Technology

Alexion Pharmaceuticals, Inc. (ALXN) and Halozyme Therapeutics, Inc. (HALO) announced a collaboration and license agreement that enables Alexion to use Halozyme’s ENHANZE® drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. The agreement provides Alexion with the opportunity for exclusive development of up to four targets, including a next generation subcutaneous formulation of ALXN1210 (ALXN1210 SC), the company’s investigational long-acting C5 complement inhibitor, to potentially further extend the dosing interval of ALXN1210 SC to once every two weeks or once per month.
- Source: news.alexionpharma
- 498
- December 12, 2017
ALXN1210 formulation inhibitor Market Views
Philippines halts sale of Sanofi’s dengue vaccine

The Philippines has suspended the sale and distribution of Sanofi’s dengue vaccine, authorities said on Tuesday, after the French pharmaceutical giant last week warned it could worsen symptoms for people who had not previously been infected.
- Source: Thenews
- 759
- December 12, 2017
Dengvaxia vaccine Sanofi’s dengue vaccine
Health2Sync raises $6M to expand its diabetes tracking and management service in Asia

Health2Sync, a Taiwan-headquartered company that offers a diabetes tracking service, has closed a $6 million Series B round aimed at expanding its business in Japan and other markets in Asia.
- Source: drugdu
- 495
- December 11, 2017
diabetes diabetes tracking service Health2Sync Series
Carmot Enters a Multi-Year Drug Discovery Collaboration With Amgen

Carmot Therapeutics, (Berkeley, CA) announced that it has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen (Thousand Oaks, CA). As part of the agreement, Carmot will apply its proprietary lead-identification technology, Chemotype Evolution, to discover and advance novel drug leads intended for the treatment of Parkinson’s disease and other selected disease areas.
- Source: Bestsellermagazine
- 532
- December 11, 2017
Amgen Market Views Parkinson’s disease
Gilead Sciences to Acquire Cell Design Labs for $567 Million

Gilead Sciences, Inc. GILD and its newly acquired cell therapy subsidiary -Kite Pharma- announced that they have inked an agreement to acquire Cell Design Labs, Inc. for $567 million. Gilead will also acquire 12.2% of Cell Design shares which are owned by Kite Pharma.
- Source: qc.nasdaq
- 429
- December 11, 2017
Apple’s First Medical Study Signals Broader Health Ambitions

Medical researchers are increasingly turning to mobile devices such as smartphones and watches as a way to monitor patients in trials, an approach they hope improves participation and accuracy but that also has limitations.
- Source: wsj
- 561
- December 11, 2017
heart rhythms mobile device Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.